CommentaryPre-emptive approach against toxoplasmosis in allogeneic haematopoietic cell transplantation. Still far away from experience in CMV
Section snippets
Author contributions
Both RS-J and JMA contributed to the final version of the manuscript.
Transparency declaration
The authors declare no conflicts of interest. No external funding was received for this work.
References (15)
- et al.
Toxoplasmosis as an early complication of allogeneic hematopoietic cell transplantation
Biol Blood Marrow Transplant
(2019) - et al.
Prevention of toxoplasmosis in transplant patients
Clin Microbiol Infect
(2008) - et al.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective
Biol Blood Marrow Transplant
(2009) - et al.
A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication
Clin Microbiol Infect
(2016) Reasons for breakthrough CMV disease in patients who receive preemptive therapy
Am J Transplant
(2012)- et al.
Toxoplasmosis in transplant recipients, Europe, 2010–2014
Emerg Infect Dis
(2018) - et al.
Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis
J Clin Microbiol
(2010)
There are more references available in the full text version of this article.
Cited by (0)
© 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.